An international study on emerging arboviral infections and blood safety.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Rajendra Piya, Faddy Helen M, Candotti Daniel, Bub Carolina B, Kutner Jose M, Drews Steven J, Charlton Carmen L, O'Brien Sheila F, Tsoi Wai-Chiu, Garcia-Otalora Michel-Andres, Reynolds Claire, Palukka Tuulia, Lehtisalo Riikka, Offergeld Ruth, Seltsam Axel, Weber-Schehl Marijke, Chenarsabz Nahid, Goto Naoko, Park Sung-Chan, Kwon So-Yong, Lieshout-Krikke Ryanne, Kopacz Aneta, Sulkowska Ewa, Șerban Oana-Alexandra, Ruta Simona, Zhiburt Eugene, Badawi Maha, Mitchel Josephine, Jentsch Ute, Herraiz Ángel Luis Pajares, Guijosa Ana Lafuente, Şahin Gülşen Özkaya, Niederhauser Christoph, Lanteri Marion C, Custer Brian, Conti Galen, Cheng Anthea, Secret Shannah, Simmonds Peter, Harvala Heli, Virology subgroup of the ISBT WP‐TTID
Аннотация
STUDY DESIGN AND METHODS: A questionnaire on arbovirus donor deferral strategies, pathogen reduction, and donation screening was distributed to members of the International Society of Blood Transfusion working party on transfusion-transmitted infectious diseases. Data from 2024 were gathered and analyzed.
RESULTS: A total of 23 survey responses were received from 21 countries. This covered a population of 1.45 billion people and 29.9 million blood donations collected in 2024. All respondents applied travel-based donor deferrals, whereas pathogen reduction, implemented by half of the respondents, was mostly applied for a selection of plasma and platelet donations. West Nile virus (WNV) was the only arbovirus blood donations were screened for by nine respondents from eight countries, with 256 donations confirmed as WNV RNA-positive in 2024. No transfusion-transmitted WNV infections were reported.
DISCUSSION: Blood safety measures remain limited and unevenly distributed globally, and in their present form, are unlikely to provide protection against the growing range of emerging arboviruses. Donor deferral may not always be a sustainable blood safety strategy alone for all blood operators, due to large-scale outbreaks associated with these viruses. While pathogen reduction methodologies are being developed to be applied to all blood components, risk assessments for (re)-emerging arboviruses, such as dengue, chikungunya, and Zika viruses, should be performed to determine if additional mitigation, such as blood donation screening, is warranted.